Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: Highly effective in a predominantly black male patient population-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: Highly effective in a predominantly black male patient population

Published:2017-10-30 Issue:2 Volume:25 Page:205-208
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Tang L.¹,Parker A.²,Flores Y.³,Dellario M.³,Dickson C.²,Amoroso A.¹⁴,Kottilil S.¹,Wilson E.¹⁴^ORCID

Affiliation:

1. Division of Clinical Care and Research; Institute of Human Virology; University of Maryland School of Medicine; Baltimore MD USA

2. Department of Pharmacy; VA Maryland Health Care System; Baltimore MD USA

3. Department of Nursing; VA Maryland Health Care System; Baltimore MD USA

4. Division of Infectious Diseases; Department of Medicine; VA Maryland Health Care System; Baltimore MD USA

Funder

Gilead Sciences

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jvh.12796/fullpdf

Reference18 articles.

1. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans;Backus;Aliment Pharmacol Ther,2015

2. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis;Kowdley;N Engl J Med,2014

3. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial;Lawitz;Lancet,2014

4. Analysis of subgroup differences in the ION-3 trial of ledipasvir-sofosbuvir in chronic hepatitis C infection;Kowdley;Open Forum Infect Dis,2015

5. Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C;O'Brien;Open Forum Infect Dis,2014

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A simple, feasible, efficient and safe treatment strategy of sofosbuvir/velpatasvir for chronic HCV/HIV-1 coinfected patients regardless of HCV genotypes: a multicenter, open-label study in China;The Lancet Regional Health - Western Pacific;2023-07

2. WITHDRAWN: Analysis of host genetic variations associated with response to anti-HCV therapies in global populations;Meta Gene;2021-03

3. Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project;Journal of Viral Hepatitis;2021-01-24

4. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals;International Journal of Antimicrobial Agents;2020-09

5. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY);Journal of Hepatology;2019-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3